Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06220760
Other study ID # US in Placenta accreta
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 20, 2024
Est. completion date September 30, 2025

Study information

Verified date January 2024
Source Assiut University
Contact Arsany Medhat, MBBS
Phone 01021808967
Email arsany2012@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Using of Ultra sound in assessment of Placenta Accreta Index to predict the surgical outcomes of Placenta accreta


Description:

Placenta accreta is a substantially life-threatening condition and one of the causes of maternal morbidity and mortality in the world. According to study done in United Kingdom, The estimated incidence of placenta accreta/increta/percreta was 1.7 per 10,000 maternities overall and 577 per 10,000 in women with both a previous caesarean delivery and placenta previa [1]. in a tertiary south Italian center, The incidence increased from 0.12% during the 1970s, to 0.31% during the 2000s [2].While in USA, the prevalence of placenta accreta was 3.7 per 1000 deliveries [3]. This increase is due to many factors. A scar of previous uterine surgery is a major risk factor for placenta accreta. Caesarean section scar is the most common one of uterine scars according to [4] especially in presence of placenta previa where the risk of placenta accreta was 3%, 11%, 40%, 61%, and 67% for the first, second, third, fourth, and fifth or greater repeat cesarean deliveries, respectively. [5] reported that both cesarean delivery morbidity and placenta accreta were positively associated with age >30 years. Previous myomectomy, multi parity, vigorous curettage are other risk factors as said [6]. More ever sub mucous leiomyoma and thermal ablation are also contributing factors to Placenta accreta [7] and lastly [8] said that uterine artery embolization is considered as a risk factor for occurrence of placenta accreta. Contrarily, inter pregnancy interval more than 60 months was associated with decreased risk of placenta accreta [9]. Because placenta accreta can lead to life-threatening blood loss, identification of these high-risk patients would be helpful in management of the pregnancy in addition to enabling the surgeon to be prepared adequately before the time of delivery. Many studies have been done on identification of placenta accreta in the third trimester by 2D ultrasound and color Doppler. There are many modalities for detection of placenta accreta ante natally [10] used 2D ultrasound and color doppler for detection of placenta accreta in 3rd trimester with sensitivity and specificity; 95.24% and 94.74% respectively for ultrasound with the most prominent feature presence of multiple lakes that represented dilated vessels extending from the placenta through the myometrium. For Doppler, the most prominent feature was the presence of interphase hypervascularity with abnormal vessels linking the placenta to the bladder, and the rate was 95.24%. As for surgery for placenta accreta, planned caesarean hysterectomy is recommended to reduce mortality and morbidity, but fertility is lost. Antenatal diagnosis of placenta accreta spectrum (PAS) can ensure multidisciplinary management at center of excellence which can reduce maternal and fetal complications. This can be established by a scoring system which provides a standardized criterion for the diagnosis and management Placenta Accreta Index (PAI). Instead of adhering to the conventional approach that involves an elective caesarean hysterectomy based on antenatal imaging, more suitable approaches should be considered from the spectrum of hemostatic and fertility-preserving options available. In our study we will investigate if the degree of adherence is related to the PAI score. Therefore, we can predict cases which will need conservative surgery or peripartum hysterectomy. And so that the surgeon be preplanned to do either hysterectomy or conservative surgery


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 154
Est. completion date September 30, 2025
Est. primary completion date December 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. pregnant women with gestational age 32 weeks or more 2. singleton pregnancy 3. known to have placenta previa (lower edge of the placenta within 5 cm from internal Os ) 4. with at least previous 1 cesarean section Exclusion Criteria: 1. the patient is active in labor 2. haemodynamically unstable

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ultrasound
The use of US to calculate placenta accreta index

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary to decide If placenta accreta index (PAI) can predict suitable type of operation needed whether Conservative management/fertility-sparing techniques or Caesarean hysterectomy 23 months
Secondary Incidence of fetal complication associated with placenta accreta 23 months
Secondary Incidence of maternal complications associated with placenta accreta 23 months
Secondary The need for ICU admission after placenta accreta surgery and its duration 23 months
See also
  Status Clinical Trial Phase
Completed NCT04579172 - Conservative Management of Morbidly Adherent Anterior Situated Placenta N/A
Completed NCT04593303 - Internal Iliac Artery Ligation During Management of Placenta Accreta Spectrum N/A
Recruiting NCT03638024 - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Not yet recruiting NCT06100640 - Paracervical Pouch in Placenta Accreta Spectrum
Completed NCT05979181 - Peripartum Cesarean Hysterectomy for Placenta Percreta
Recruiting NCT04609527 - Management of Placenta Accreta Spectrum Phase 2/Phase 3
Recruiting NCT06185894 - The Role of Using Tourniquet in Decreasing Bleeding in Placenta Accreta Spectrum Cases N/A
Completed NCT04573452 - Galectin-3 and Placenta Accreta
Not yet recruiting NCT03273569 - PDIUC Protocol for Placental Accreta N/A
Completed NCT03707132 - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Not yet recruiting NCT05104177 - Effectivness of Conservative Techniques in Management of PAS
Completed NCT02806024 - Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study Phase 4
Active, not recruiting NCT02784886 - Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta N/A
Recruiting NCT05070689 - Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS) N/A
Completed NCT05813743 - Detection of Urinary Bladder Wall Involvement in Abnormally Invasive Placenta (AIP) by 3D Ultrasonography N/A
Withdrawn NCT04003428 - Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA) N/A
Completed NCT04161521 - Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital N/A
Recruiting NCT05139498 - Conservative Management for PAS Pilot N/A
Not yet recruiting NCT03530475 - Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler N/A
Recruiting NCT05922397 - Placenta Accreta Spectrum Topographic Classification

External Links